Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial

被引：0
|
作者：
Krempf, M. [1 ]
Astrup, A. [2 ]
le Roux, C. [3 ]
Fujioka, K. [4 ]
Greenway, F. [5 ]
Halpern, A. [6 ]
Lau, D. C. W. [7 ]
Violante Ortiz, R. [8 ]
Wilding, J. P. H. [9 ]
Jensen, C. B. [10 ]
Lillleore, S. K. [10 ]
Pi-Sunyer, X. [11 ]
机构：
[1] CHRU Nantes, Clin Endocrinol, Nantes, France
[2] Univ Copenhagen, DK-1168 Copenhagen, Denmark
[3] Univ Coll Dublin, Dublin, Ireland
[4] Scripps Clin, La Jolla, CA USA
[5] Louisiana State Univ, Baton Rouge, LA 70803 USA
[6] Univ Sao Paulo, Sch Med, BR-05508 Sao Paulo, Brazil
[7] Univ Calgary, Calgary, AB T2N 1N4, Canada
[8] Inst Mexicano Seguro Social, Ciudad Madero, Mexico
[9] Univ Liverpool, Liverpool L69 3BX, Merseyside, England
[10] Novo Nordisk AS, Soborg, Denmark
[11] Columbia Univ, New York, NY USA
来源：
DIABETOLOGIA | 2014年 / 57卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
903
引用
收藏
页码：S368 / S368
页数：1
相关论文
共 50 条
  • [1] Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial
    le Roux, C.
    Lau, D. C. W.
    Astrup, A.
    Fujioka, K.
    Greenway, F.
    Halpern, A.
    Krempf, M.
    Violante Ortiz, R.
    Wilding, J. P. H.
    Jensen, C. B.
    Svendsen, C. B.
    Pi-Sunyer, X.
    DIABETOLOGIA, 2014, 57 : S338 - S338
  • [2] Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial
    Fujioka, K.
    Wilding, J. P. H.
    Astrup, A.
    Greenway, F.
    Halpern, A.
    Krempf, M.
    Lau, D. C. W.
    le Roux, C.
    Violante Ortiz, R.
    Jensen, C. B.
    Lillleore, S. K.
    Pi-Sunyer, X.
    DIABETOLOGIA, 2014, 57 : S368 - S369
  • [3] Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors: SCALE obesity and prediabetes randomised, double-blind, placebo-controlled 3-year trial
    le Roux, C. W.
    Astup, A.
    Greenway, F.
    Krempf, M.
    Vettor, R.
    Manning, L. Shapiro
    Lilleore, S. K.
    Fujioka, K.
    DIABETOLOGIA, 2016, 59 : S329 - S329
  • [4] Liraglutide 3.0 Mg Improves Body Weight and Cardiometabolic Risk Factors in Overweight or Obese Adults without Diabetes: The Scale Obesity and Prediabetes Randomized, Double-Blind, Placebo-Controlled 56-Week Trial
    Le Roux, Carel
    Astrup, Arne
    Fujioka, Ken
    Greenway, Frank Lyons
    Halpern, Alfredo
    Krempf, Michel
    Lau, David C.
    Ortiz, Rafael Violante
    Wilding, John
    Jensen, Christine Bjorn
    Pi-Sunyer, F. Xavier
    ENDOCRINE REVIEWS, 2014, 35 (03)
  • [5] Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial
    Pi-Sunyer, X.
    Fujioka, K.
    le Roux, C.
    Astrup, A.
    Greenway, F.
    Halpern, A.
    Krempf, M.
    Lau, D. C. W.
    Ortiz, R. Violante
    Jensen, C. B.
    Lillleore, S. K.
    Wilding, J. P. H.
    DIABETOLOGIA, 2014, 57 : S37 - S37
  • [6] Liraglutide 3.0 mg improves insulin secretion and action in overweight/obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial
    Lau, D. C. W.
    Wilding, J. P. H.
    Astrup, A.
    Fujioka, K.
    Greenway, F.
    Halpern, A.
    Krempf, M.
    le Roux, C.
    Violante Ortiz, R.
    Overgaard, R. V.
    Jensen, C. B.
    Pi-Sunyer, X.
    DIABETOLOGIA, 2014, 57 : S358 - S358
  • [7] Effect of liraglutide 3.0/1.8 mg on body weight and cardiometabolic risk factors in overweight/obese adults with type 2 diabetes: SCALE diabetes randomised, double-blind, 56-week trial
    Bode, B.
    DeFronzo, R.
    Bergenstal, R.
    Kushner, R.
    Lewin, A.
    Skjoth, T. V.
    Jensen, C. B.
    Davies, M.
    DIABETOLOGIA, 2014, 57 : S83 - S83
  • [8] In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of Type 2 diabetes: SCALE obesity and pre-diabetes trial
    Wilding, J.
    Astrup, A.
    Fujioka, K.
    Greenway, F.
    Krempf, M.
    Lau, D.
    Le Roux, C. W.
    Lilleore, S. K.
    Jensen, T.
    Violante Ortiz, R.
    DIABETIC MEDICINE, 2015, 32 : 71 - 71
  • [9] Liraglutide 3.0mg results in significant weight loss and improvements in cardiometabolic risk factors compared with liraglutide 1.8mg or placebo: a randomised, double-blind, 56 week trial in overweight/obese adults with Type 2 diabetes (SCALE diabetes)
    Davies, M. J.
    DeFronzo, R. A.
    Bergenstal, R. M.
    Bode, B. W.
    Kushner, R.
    Noctor, M.
    Jensen, T.
    Lewin, A.
    DIABETIC MEDICINE, 2015, 32 : 72 - 72
  • [10] Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre-diabetes trial
    Wilding, J.
    Lau, D.
    Astrup, A.
    Fujioka, K.
    Greenway, F.
    Krempf, M.
    Le Roux, C. W.
    Violante Ortiz, R.
    Lilleore, S. K.
    Jensen, T.
    Pi-Sunyer, X.
    DIABETIC MEDICINE, 2015, 32 : 70 - 70
12345